|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||33.37|
|Dividend & Yield||0.30 (0.77%)|
|1y Target Est||33.82|
Amgen’s (AMGN) Xgeva was launched commercially in 2010 and is marketed primarily in the US and Europe. The drug crossed the $1 billion annual revenue mark in 2013.
NORTHVALE, N.J., May 22, 2017-- Elite Pharmaceuticals, Inc., today announced the acquisition of an approved and currently marketed Abbreviated New Drug Application for Trimipramine Maleate Capsules 25, ...
Dr. Reddy’s Laboratories Ltd. announced today that it has received approval from the U.S. Food and Drug Administration to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil® , for intravenous use, in the United States market.